Proteomics in MEDA-PKD Registry
In an ongoing multicenter longitudinal observational registry of adults with autosomal dominant polycystic kidney disease, MEDA-PKD demonstrates a harmonized platform for integrating proteomics with clinical data and reports associations between tolvaptan initiation and estimated glomerular filtration rate trajectory measures.
Evidence
MEDA-PKD is an interactive, near-real-time analytics platform built from the German AD(H)PKD Tolvaptan Registry, an ongoing multicenter, longitudinal observational study. The registry enrolls adults aged 18 years or older with autosomal dominant polycystic kidney disease who are undergoing evaluation or treatment with tolvaptan in routine care or study follow-up. Participants gave written informed consent before inclusion. The stated registry purpose is systematic documentation of clinical, laboratory, imaging, and patient-reported data, creating a longitudinal real-world dataset rather than a randomized treatment comparison. [pmid:42901931]
The platform harmonizes clinical routine and research data, then applies automated analysis and dynamic visualization. Its stated molecular component is integration of proteomics data with registry information, alongside secure individual patient-level data access. Thus, the proteomics relevance is infrastructural: molecular information is placed in the same analytic environment as longitudinal clinical and routine-care data. The source does not provide a proteomics-specific outcome estimate or a clinical performance result for a protein model, so the reported treatment-trajectory results should not be interpreted as direct evidence for a particular proteomic signature. [pmid:42901931]
As of March 2026, MEDA-PKD visualized data from 1,735 patients, with mean follow-up of 796 days. For the tolvaptan slope analysis, 332 patients initiating therapy were included. The report also describes a linear mixed-effects model using all estimated glomerular filtration rate values from patients who at some point received tolvaptan, without imposing the stated minimum availability criterion of at least three estimated glomerular filtration rate values over at least one year. These analytic choices frame the comparison as within-registry, longitudinal observational analysis. [pmid:42901931]
In the linear mixed-effects model, the estimated rate of decline in estimated glomerular filtration rate was −3.62 ml/min/1.73 m²/yr before treatment and −3.01 ml/min/1.73 m²/yr during treatment. The reported absolute attenuation was 0.61 ml/min/1.73 m²/yr, with a 95% confidence interval of 0.07 to 1.16 and p = 0.028. The source additionally reports a relative reduction in the rate of decline of 16.9%, with a 95% confidence interval of 3.3–30.6%. These are model-based estimates of a before-versus-during-treatment pattern in registry participants, not randomized estimates. [pmid:42901931]
Separately from the slope estimate, tolvaptan initiation was associated with an acute reduction in estimated glomerular filtration rate level of approximately 2.5 ml/min/1.73 m², with a 95% confidence interval of 1.1–3.9 and p < 0.001. The authors describe this pattern as consistent with the expected hemodynamic effect of tolvaptan. Sex-specific slope comparisons also reached statistical significance, with men reported to have greater response than women; the reported p-values were 0.0012 for men and 0.035 for women. The supplied evidence does not provide the corresponding sex-specific effect sizes or confidence intervals. [pmid:42901931]
The platform is also described as reproducing established autosomal dominant polycystic kidney disease progression patterns, including sex- and total-kidney-volume-based differences in estimated glomerular filtration rate decline. This use case situates proteomics among other longitudinal data modalities rather than establishing a molecularly guided intervention. The platform’s principal contribution in the reported material is the capacity to connect clinical trajectories, routine data, imaging, and molecular resources for analysis as data accrue. [pmid:42901931]
Analysis — Observational Registry Integration
The reported pattern is consistent with an observational registry design in which people evaluated for or treated with tolvaptan contribute longitudinal measurements under routine-care or study-follow-up conditions. Comparing estimated glomerular filtration rate before and during treatment can characterize temporal associations within the recorded data, while the linear mixed-effects model incorporates repeated values from patients who at some point received tolvaptan. However, treatment initiation, measurement frequency, baseline disease trajectory, and follow-up availability arise through the registry’s selection and care processes rather than random allocation. Consequently, the attenuation estimate and acute estimated glomerular filtration rate reduction describe observed associations in this population and analytic framework, not causal effects of treatment. [pmid:42901931]
Proteomics is explicitly integrated into MEDA-PKD, but the available results do not link a named protein measurement, proteomic model, or molecular subgroup to the estimated glomerular filtration rate findings. The appropriate interpretation is therefore bounded: the study demonstrates a data-integration platform that can place proteomics alongside longitudinal clinical information, while the reported quantitative analysis concerns estimated glomerular filtration rate trajectories around tolvaptan exposure. Statistical significance in the reported models does not itself establish clinical significance. [pmid:42901931]
Limitations
The observational design cannot establish causation. Selection into evaluation or treatment with tolvaptan, as well as the availability and timing of longitudinal estimated glomerular filtration rate measurements, may shape the observed before-versus-during comparison. The linear mixed-effects analysis included all estimated glomerular filtration rate values from patients who at some point received tolvaptan and did not impose the minimum measurement-availability criterion described in the methods; this broadens included data but does not remove the design’s nonrandomized comparison structure. [pmid:42901931]
Generalizability is constrained by the availability of structured local hospital-information-system data, interoperability with relevant application programming interfaces, and governance arrangements for use of routine clinical data in research. The source states that these conditions vary substantially between jurisdictions. In addition, although proteomics integration is reported, no proteomics-specific outcome estimate or clinical performance result is provided in the available evidence, limiting conclusions about protein-level associations or utility. [pmid:42901931]